Kingworld Medicines Group Ltd. AI Stock Analysis
Want to see HK:1110 full AI Analyst Report?
Kingworld Medicines Group Ltd. (1110) AI Stock Analysis
Kingworld Medicines Group Ltd.
(HKEX:1110)
The stock’s mid-50s score reflects weakening financial quality as thin margins, lower profits, and rising leverage increase risk despite ongoing profitability. Supportive technicals, with the price trending above key short- and medium-term moving averages and moderate momentum, help the score from falling lower. Valuation is only modestly favorable, as a high dividend yield is offset by a not-cheap P/E multiple relative to volatile and currently subdued earnings.
Kingworld Medicines Group Ltd. (1110) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 221.18M
- Dividend Yield
- 8.45%
- Average Volume (3M)
- 1.90M
- Price to Earnings (P/E)
- 16.9
- Beta (1Y)
- 0.22
- Revenue Growth
- -13.82%
- EPS Growth
- 112.24%
- Country
- Hong Kong
- Employees
- 711
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Distribution
Kingworld Medicines Group Ltd. Business Overview & Revenue Model
Company Description
Kingworld Medicines Group Limited functions as an investment holding company primarily engaged in the distribution of imported, branded pharmaceutical and healthcare items. The company also supplies a range of medical products, health goods, and gene...
How the Company Makes Money
Kingworld Medicines Group Ltd. primarily makes money by selling pharmaceutical and healthcare products through wholesale/distribution and related sales activities. Key revenue streams typically include: (1) distribution/wholesale revenue from purchas...
Kingworld Medicines Group Ltd. Financial Statement Overview
Summary
Revenue and profit have recently declined, with net margin near 1% and earnings more volatile, while rising leverage and inconsistent free cash flow offset a still-profitable, moderately capitalized balance sheet.
Income Statement
42NeutralBalance Sheet
58NeutralCash Flow
50Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 787.87M | 917.34M | 1.06B | 1.08B | 957.70M | 847.39M |
| Gross Profit | 240.04M | 247.91M | 270.45M | 280.67M | 277.63M | 263.60M |
| EBITDA | 80.78M | 82.70M | 110.77M | 125.48M | 118.07M | 116.00M |
| Net Income | 11.47M | 11.28M | 41.56M | 38.10M | 22.74M | 30.32M |
Balance Sheet | ||||||
| Total Assets | 1.30B | 1.44B | 1.42B | 1.34B | 1.26B | 1.21B |
| Cash, Cash Equivalents and Short-Term Investments | 188.35M | 274.70M | 249.60M | 194.03M | 256.17M | 198.41M |
| Total Debt | 438.04M | 434.05M | 402.44M | 354.43M | 290.68M | 238.96M |
| Total Liabilities | 648.92M | 753.86M | 710.04M | 638.30M | 569.15M | 493.19M |
| Stockholders Equity | 596.45M | 617.97M | 639.79M | 619.03M | 615.58M | 616.90M |
Cash Flow | ||||||
| Free Cash Flow | -1.18M | 54.92M | 94.73M | -63.25M | 93.64M | 22.88M |
| Operating Cash Flow | 38.39M | 84.56M | 135.82M | 42.28M | 186.55M | 81.20M |
| Investing Cash Flow | -15.51M | -20.11M | -27.64M | -120.63M | -84.05M | -50.84M |
| Financing Cash Flow | -60.57M | -30.82M | -47.61M | 4.37M | -51.31M | -87.20M |
Kingworld Medicines Group Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1110, the sentiment is Negative. The current price of 0.38 is below the 20-day moving average (MA) of 0.38, below the 50-day MA of 0.38, and below the 200-day MA of 0.44, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 48.16 is Neutral, neither overbought nor oversold. The STOCH value of 21.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1110.
Kingworld Medicines Group Ltd. Peers Comparison
Overall Rating
HK:023986Outperform
HK:089758.6Neutral
HK:111055.1Neutral
HK:085854Neutral
HK:149841Neutral
HK:045540Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 86Outperform | HKD 738.59M | 7.38 | 13.59% | 8.44% | 10.63% | 39.44% | |
| 59Neutral | HKD 406.75M | 101.39 | 0.34% | ― | -8.30% | -44.44% | |
| 55Neutral | HKD 227.44M | 16.86 | 1.89% | 8.45% | -13.82% | 112.24% | |
| 54Neutral | HKD 153.70M | -0.14 | -154.56% | ― | -7.12% | -523.61% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 41Neutral | HKD 117.69M | -3.87 | -21.66% | ― | -6.71% | 43.14% | |
| 40Underperform | HKD 154.80M | -2.21 | -14.55% | ― | 12.89% | -2.56% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:1110 | Kingworld Medicines Group Ltd. | 0.38 | -0.14 | -26.47% | |
| HK:0858 | Extrawell Pharmaceutical Holdings Limited | 0.05 | -0.03 | -32.91% | |
| HK:0455 | Tianda Pharmaceuticals Ltd. | 0.07 | -0.05 | -40.50% | |
| HK:0897 | Wai Yuen Tong Medicine Holdings Limited | 0.36 | -0.09 | -18.89% | |
| HK:1498 | PuraPharm Corp. Ltd. | 0.22 | -0.16 | -42.11% | |
| HK:0239 | Pak Fah Yeow International Limited | 2.37 | 0.11 | 5.05% |
Kingworld Medicines Group Ltd. Corporate Events
Kingworld Medicines Narrows Shareholder Loss Despite Sharp Revenue Decline
Kingworld Medicines Group Ltd., a pharmaceutical and healthcare products distributor in mainland China with supplementary income from investment properties and equity interests, reported mixed interim results for the six months ended 30 June 2026. Th...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 15, 2026
